Statements of Income
Performance by Subgroup and Segment
Bayer Links
Management Report
Performance by Subgroup and Segment
Changes in corporate structure
Our business activities are grouped into the HealthCare, CropScience and MaterialScience subgroups.
As of March 31, 2007, our interest in the voting capital of Bayer Schering Pharma AG, Berlin, Germany, amounted to 96.3 percent. The acquired business of Schering, Berlin, Germany, is included in the Pharmaceuticals segment of the HealthCare subgroup as of June 23, 2006. This business is not included in the figures for the first quarter of 2006.
The names “Bayer Schering Pharma” or “Schering” as used in this report always refer to Bayer Schering Pharma AG, Berlin, Germany, or its predecessor, Schering AG, Berlin, Germany, respectively. The reference to Bayer Schering Pharma AG or Schering AG also includes business conducted by affiliated entities in countries outside Germany. Bayer Schering Pharma AG and Schering-Plough Corporation, New Jersey, United States, are unaffiliated companies that have been totally independent of each other for many years.
The commentaries in this report relate exclusively to continuing operations, except where specific reference is made to discontinued operations or to a total value (total). The Diagnostics Division and H.C. Starck, both now divested, and the Wolff Walsrode activities, divestment of which is pending, are reported as discontinued operations. The prior-year data are restated accordingly.
As of March 31, 2007, our interest in the voting capital of Bayer Schering Pharma AG, Berlin, Germany, amounted to 96.3 percent. The acquired business of Schering, Berlin, Germany, is included in the Pharmaceuticals segment of the HealthCare subgroup as of June 23, 2006. This business is not included in the figures for the first quarter of 2006.
The names “Bayer Schering Pharma” or “Schering” as used in this report always refer to Bayer Schering Pharma AG, Berlin, Germany, or its predecessor, Schering AG, Berlin, Germany, respectively. The reference to Bayer Schering Pharma AG or Schering AG also includes business conducted by affiliated entities in countries outside Germany. Bayer Schering Pharma AG and Schering-Plough Corporation, New Jersey, United States, are unaffiliated companies that have been totally independent of each other for many years.
The commentaries in this report relate exclusively to continuing operations, except where specific reference is made to discontinued operations or to a total value (total). The Diagnostics Division and H.C. Starck, both now divested, and the Wolff Walsrode activities, divestment of which is pending, are reported as discontinued operations. The prior-year data are restated accordingly.
Key Data by Subgroup and Segment
| Sales | EBIT before special items* | EBITDA before special items* | EBITDA margin before special items* | |||||
| € million | 1st Quarter 2006 | 1st Quarter 2007 | 1st Quarter 2006 | 1st Quarter 2007 | 1st Quarter 2006 | 1st Quarter 2007 | 1st Quarter 2006 | 1st Quarter 2007 |
| HealthCare | 2,203 | 3,610 | 385 | 624 | 465 | 948 | 21.1% | 26.3% |
| Pharmaceuticals | 1,148 | 2,495 | 207 | 420 | 246 | 711 | 21.4% | 28.5% |
| Consumer Health | 1,055 | 1,115 | 178 | 204 | 219 | 237 | 20.8% | 21.3% |
| CropScience | 1,771 | 1,786 | 408 | 447 | 551 | 584 | 31.1% | 32.7% |
| Crop Protection | 1,413 | 1,434 | 285 | 343 | 406 | 461 | 28.7% | 32.1% |
| Environmental Science/BioScience | 358 | 352 | 123 | 104 | 145 | 123 | 40.5% | 34.9% |
| MaterialScience | 2,486 | 2,608 | 423 | 291 | 539 | 409 | 21.7% | 15.7% |
| Materials | 710 | 739 | 132 | 38 | 170 | 80 | 23.9% | 10.8% |
| Systems | 1,776 | 1,869 | 291 | 253 | 369 | 329 | 20.8% | 17.6% |
| Reconciliation | 331 | 331 | (39) | 13 | 9 | 49 | 2.7% | 14.8% |
| Continuing operations | 6,791 | 8,335 | 1,177 | 1,375 | 1,564 | 1,990 | 23.0% | 23.9% |
2006 figures restated
* for definition see Bayer Group Key Data, also Bayer Stock.
* for definition see Bayer Group Key Data, also Bayer Stock.
Bookmark this page
E-mail this page
Advanced Search
